netFormulary
 Report : Medicines with links to NICE 16/08/2018 09:46:26

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treament of Crohns disease
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adefovir Dipivoxil 05.03.03 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Aflibercept 11.08.02 Formulary NICE TA294: Macular degeneration (wet age related)
Alitretinoin 13.05.01 Restricted Use NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TAG156: Anti-D in pregnant women
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis (2017)
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Boceprevir 05.03.03 Formulary NICE Guidance 2012
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bosutinib 08.01 Restricted Use NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia (2016)
Botulinum Toxin Type A 04.09.03 Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.02 Restricted Use NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (2017)
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carfilzomib 08.01.05 Restricted Use NICE TA457 Carfilzomib for previously treated multiple myeloma (2017)
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab Pegol 10.01.03 Formulary NICE TA186: Rheumatoid arthritis - certolizumab pegol
Ciclosporin 11.04.02 Restricted Use NICE TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Crizotinib 08.01.05 Restricted Use NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (2016)
Dabigatran etexilate 02.08.02 Restricted Use NICE TA249: Dabigatran for Stroke prevention in AF
Dasatinib 08.01.05 Formulary NICE TA241:CML for whom treatment with imatinib has failed because of intolerance
Denosumab (osteoporosis) 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TAG 229: Dexamethasone intravitreal implant for the treatment of macular oedema
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone 02.03.02 Restricted Use NICE TA197: Atrial fibrillation - dronedarone
Eltrombopag 09.01.04 Formulary NICE guidance 2010
Entecavir 05.03.03 Formulary NICE TA153: Hepatitis B - entecavir
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Formulary NICE TA35: Arthritis (juvenile idiopathic) - etanercept
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Exenatide 06.01.02.03 Formulary NICE TAG 248- MR exenatide
Ezetimibe 02.12 Formulary NICE TA132: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone acetonide 11.04.02 Formulary NICE TA 301 Diabetic Macular oedema
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA233: Ankylosing spondylitis - golimumab
Ibrutinib 08.01.05 Restricted Use NICE TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia (2017)
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Ivabradine 02.06.03 Formulary TA267 NICE Guidance in Chronic Heart Failure
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Methylprednisolone 06.03.02 Formulary NICE: Multiple Sclerosis; management in primary and secondary care.
Naltrexone Hydrochloride 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Nivolumab 08.02 Restricted Use NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (2017)
Obinutuzumab 08.02.03 Restricted Use Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Omalizumab 03.04.02 Formulary NICE TA201: Asthma (in children) - omalizumab
Omalizumab 03.04.02 Formulary NICE TA133: Asthma (uncontrolled) - omalizumab
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Palbociclib 08.01.05 Restricted Use NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (2017)
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pixantrone 08.01.02 Restricted Use NICE TA 306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide 08.02.04 Restricted Use NICE TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (2017)
Ponatinib 08.01.05 Restricted Use NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (2018)
Prasugrel 02.09 Formulary NICE TA182: Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Prucalopride for the treatment of chronic constipation in women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE quick reference guide on osteoporosis
Ranibizumab 11.08.02 Formulary NICE TA237: diabetic macular oedema
Ranolazine 02.06.03 Formulary NICE Guidance on Stable Angina
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribociclib 08.01.05 Restricted Use NICE TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (2017)
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkins) - rituximab
Rituximab 08.02.03 Formulary NICE TA110: Follicular lymphoma - rituximab Non-Hodgkins lymphoma - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rituximab (rheumatology) 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Restricted Use NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Restricted Use NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in patients with AF
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Sarilumab 10.01.03 Formulary NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis (2017)
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Telaprevir 05.03.03 Formulary NICE Guidance 2012
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B - tenofovir disoproxil fumarate
Ticagrelor 02.09 Formulary NICE TAG 236:Treatment of Acute coronary syndrome
Tocilizumab 10.01.03 Formulary NICE TA198: Rheumatoid arthritis - tocilizumab
Tofacitinib 10.01.03 Formulary NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis (2017)
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA91: Topotecan for ovarian cancer
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Ustekinumab 13.05.03 Formulary NICE TA170: Psoriasis - ustekinumab
Venetoclax 08.01.05 Restricted Use NICE TA487 Venetoclax for treating chronic lymphocytic leukaemia (2017)
Zolpidem 04.01.01 Restricted Use NICE TAG 77 : Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TAG 77 :Zaleplon, zolpidem and zopiclone for the management of insomnia
The Rotherham